Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

Back to Search
Print
Bookmark Trial

NCT00632385

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Irvine, California, 92618, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Migraine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of migraine headache according to International Headache Society criteria and migraine headaches for at least 1 year

- Eletriptan naive

- Previously treated with rizatriptan and failed to achieve a satisfactory response within the past 12 months

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Non-migraine headaches on average more than 6 days per month or have less than 24
hours of freedom from headache between migraine attacks


- Migraine attacks that are atypical or chronic daily headaches


- A history of migraine with prolonged aura, familial hemiplegic migraine, basilar
migraine, migrainous infarction, migraine aura without headache, migraine with acute
onset aura

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

MigraineA Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
NCT01981486
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MigraineA Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
NCT00174395
  1. Edmonton, Alberta
  2. Chilliwack, British Columbia
  3. Coquitlam, British Columbia
  4. Langley, British Columbia
  5. North Vancouver, British Columbia
  6. Penticton, British Columbia
  7. Winnipeg, Manitoba
  8. Bathurst, New Brunswick
  9. Moncton, New Brunswick
  10. St. John's, Newfoundland and Labrador
  11. Halifax, Nova Scotia
  12. Truro, Nova Scotia
  13. Bolton, Ontario
  14. Brampton, Ontario
  15. Corunna, Ontario
  16. Fort Erie, Ontario
  17. Hamilton, Ontario
  18. London, Ontario
  19. Markham, Ontario
  20. Mississauga, Ontario
  21. Newmarket, Ontario
  22. Niagara Falls, Ontario
  23. Woodstock, Ontario
  24. Montague, Prince Edward Island
  25. Cowansville, Quebec
  26. Drummondville, Quebec
  27. Granby, Quebec
  28. Montreal, Quebec
  29. Sainte Julie, Quebec
  30. Sherbrooke, Quebec
  31. Regina, Saskatchewan
  32. Mount Pearl,
  33. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MigraineA Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
NCT00510419
  1. San Francisco, California
  2. Stamford, Connecticut
  3. Chicago, Illinois
  4. Ann Arbor, Michigan
  5. Springfield, Missouri
  6. Pittsburgh, Pennsylvania
  7. Memphis, Tennessee
  8. Dallas, Texas
  9. Houston, Texas
  10. San Antonio, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MigraineSafety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
NCT00634985
  1. Capa, Istanbul
  2. Gaziantep,
  3. Istanbul,
  4. Izmir,
  5. Samsun,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
Official Title  ICMJE An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy
Brief Summary To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Migraine
Intervention  ICMJE Drug: Eletriptan
40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
Study Arms  ICMJE Experimental: A
Intervention: Drug: Eletriptan
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 22, 2011)		127
Original Actual Enrollment  ICMJE
 (submitted: March 3, 2008)		123
Actual Study Completion Date  ICMJE August 2003
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of migraine headache according to International Headache Society criteria and migraine headaches for at least 1 year
  • Eletriptan naive
  • Previously treated with rizatriptan and failed to achieve a satisfactory response within the past 12 months

Exclusion Criteria:

  • Non-migraine headaches on average more than 6 days per month or have less than 24 hours of freedom from headache between migraine attacks
  • Migraine attacks that are atypical or chronic daily headaches
  • A history of migraine with prolonged aura, familial hemiplegic migraine, basilar migraine, migrainous infarction, migraine aura without headache, migraine with acute onset aura
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00632385
Other Study ID Numbers  ICMJE A1601092
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP